肺大细胞神经内分泌肿瘤诊断与治疗研究进展
Advances in Diagnosis and Treatment of Lung Large Cell Neuroendocrine Tumors
摘要: 肺大细胞神经内分泌肿瘤(Large cell neuroendocrine lung cancer, LCNEC)是一种来源于支气管黏膜Kulchitsky细胞的恶性肿瘤，临床发病率比较少见，肺神经内分泌肿瘤占所有肺肿瘤的15%~20%，Jiang等报道766例接受手术的肺癌患者中，其中22例为LCNEC。LCNEC更常见于外周肿瘤，少数可位于中心位置。大部分患者出现的临床表现与常见肺部肿瘤相似，影像学诊断缺乏特异性，随着免疫组织化学的发展，近年来更多肿瘤患者被确诊。由于恶性程度高，早期诊断并以手术为主的综合治疗为首选治疗方式。
Abstract: Large cell neuroendocrine lung cancer (LCNEC) is a malignant tumor originated from bronchial mu-cosa Kulchitsky cells, with a relatively rare clinical incidence. Lung neuroendocrine tumors account for 15%~20% of all lung tumors. Jiang et al. reported that among 766 lung cancer patients who un-derwent surgery, 22 cases were LCNEC. LCNEC is more common in peripheral tumors, and a few may be centrally located. The clinical manifestations of most patients are similar to common lung tumors, and imaging diagnosis lacks specificity. With the development of immunohistochemistry, more pa-tients with tumors have been diagnosed in recent years. Due to the high degree of malignancy, early diagnosis combined with surgery is the preferred treatment.
文章引用：山春玲, 拉周措毛. 肺大细胞神经内分泌肿瘤诊断与治疗研究进展[J]. 临床医学进展, 2022, 12(5): 4166-4171. https://doi.org/10.12677/ACM.2022.125604

参考文献

[1] Fasano, M., Della Corte, C.M., Papaccio, F., et al. (2015) Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. Journal of Thoracic Oncology, 10, 1133-1141. [Google Scholar] [CrossRef] 
[2] Garcia-Yuste, Matilla, J.M., Alvarez-Gago, T., et al. (2000) Prognostic Factors in Neuroendocrine Lung Tumors: A Spanish Multicenter Study. The Annals of Thoracic Surgery, 70, 258-263. [Google Scholar] [CrossRef] 
[3] Akata, S., Okada, S., Maeda, J., et al. (2007) Computed Tomographic Findings of Large Cell Neuroendocrine Carcinoma of the Lung. Clinical Imaging, 31, 379-384. [Google Scholar] [CrossRef] [PubMed]
[4] Rivera, M.P. and Mehta, A.C. (2007) Initial Diagnosis of Lung Cancer. ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest, 132, 131. [Google Scholar] [CrossRef] [PubMed]
[5] Fernandez, F.G. and Battafarano, R.J. (2006) Large-Cell Neuroendocrine Carcinoma of the Lung: An Aggressive Neuroendocrine Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 18, 206-210. [Google Scholar] [CrossRef] [PubMed]
[6] Travis, W.D., Rush, W., Flieder, D.B., et al. (1998) Survival Analysis of 200 Pulmonary Neuroendocrine Tumors with Clarification of Criteria for Atypical Carcinoid and Its Separation from Typical Carcinoid. The American Journal of Surgical Pathology, 22, 934-944. [Google Scholar] [CrossRef] [PubMed]
[7] Bari, M.F., Brown, H., Nicholson, A.G., et al. (2014) BAI3, CDX2 and VIL1: A Panel of Three Antibodies to Distinguish Small Cell from Large Cell Neuroendocrine Lung Carcinomas. Histopathology, 64, 547-556. [Google Scholar] [CrossRef] [PubMed]
[8] Travis, W.D., Brambilla, E., Noguchi, M., et al. (2013) Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Socie-ty/European Respiratory Society classification. Archives of Pathology & Laboratory Medicine, 137, 668-684. [Google Scholar] [CrossRef] 
[9] Rekhtman, N., Pietanza, M.C., Hellmann, M.D., et al. (2016) Next-Generation Sequencing of Pulmonary Large-Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-Like and Non-Small Cell Carcino-ma-Like Subsets. Clinical Cancer Research, 22, 3618-3629. [Google Scholar] [CrossRef] 
[10] Miyoshi, T., Umemura, S., Matsumura, Y., et al. (2017) Genomic Profiling of Large Cell Neuroendocrine Carcinoma of the Lung. Clinical Cancer Research, 23, 757-765. [Google Scholar] [CrossRef] 
[11] LaPoint, R.J.A., Bourne, P.A., Wang, H.L., et al. (2007) Coexpression of c-Kit and bcl-2 in Small Cell Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung. Applied Im-munohistochemistry & Molecular Morphology, 15, 401-406. [Google Scholar] [CrossRef] [PubMed]
[12] Eichhorn, F., Dienemann, H., Muley, T., et al. (2015) Predictors of Survival after Operation among Patients with Large Cell Neuroendocrine Car-cinoma of the Lung. The Annals of Thoracic Surgery, 99, 983-989. [Google Scholar] [CrossRef] [PubMed]
[13] Iyoda, A., Hiroshima, K., Moriya, Y., et al. (2006) Prospective Study of Adjuvant Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinoma. The Annals of Thoracic Surgery, 82, 1802-1807. [Google Scholar] [CrossRef] [PubMed]
[14] Le Treut, J., Sauh, M.C., Lena, H., et al. (2013) Multicentre Phase II Study of Cisplatin-Etoposide Chemotherapy for Advanced Large-Cell Neuroendocrine Lung Carcinoma: The GFPC 0302 Study. Annals of Oncology, 24, 1548-1552. [Google Scholar] [CrossRef] [PubMed]
[15] Niho, S., Kenmotsu, H., Sekine, I., Ishii, G., et al. (2013) Combination Chemothera-py with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study. Journal of Tho-racic Oncology, 8, 980-984. [Google Scholar] [CrossRef] 
[16] Rieber, J., Schmitt, J., Warth, A., et al. (2015) Outcome and Prognostic Factors of Multimodal Therapy for Pulmonary Large-Cell Neuroendocrine Carcinomas. European Journal of Medical Research, 20, 64. [Google Scholar] [CrossRef] [PubMed]
[17] Derks, J.L., Leblay, N., Thunnissen, E., et al. (2018) Molecular Subtypes of Pulmonary Large-Cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Clinical Cancer Research, 24, 33-42. [Google Scholar] [CrossRef] 
[18] Tsuruoka, K., Horinouchi, H., Goto, Y., et al. (2017) PD-L1 Expression in Neuroendocrine Tumors of the Lung. Lung Cancer, 108, 115-120. [Google Scholar] [CrossRef] [PubMed]
[19] Patel, S.P., Othus, M., Chae, Y.K., et al. (2020) A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Non-Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 26, 2290-2296. [Google Scholar] [CrossRef] 

为你推荐